Veenat, Geftinat, Soranib

Published: 01st March 2011
Views: N/A

Veenat, Geftinat, Soranib


Veenat is a very effective drug in the treatment of certain types of leukemia (cancer that begins in the white blood cells) and other cancers of the blood cells. It is also used to treat gastrointestinal stromal tumors.


Geftinat is used to treat non-small cell lung cancer. It works by blocking the action of a certain naturally occurring substance that may be needed to help cancer cells multiply.


Soranib is used to treat non-small cell lung cancer. It works by blocking the action of a certain naturally occurring substance that may be needed to help cancer cells multiply.


VEENAT 100mg : Each capsule contains Imatinib Mesylate equivalent to Imatinib 100mg.





matinib Mesylate is a protein - tyrosine kinase inhibitor that inhibits the Bcr-Abl tyrosine kinase, the constitutive abnormal tyrosine kinase created by the Philadelphia Chromosome abnormality in Chronic Myeloid Leukemia (CML).





Indications:


VEENAT (Imatinib Mesylate) is indicated for the treatment of patients with Philadelphia Chromosome positive Chronic Myeloid Leukemia (CML) in blast crisis, accelerated phase, or in chronic phase.





Dosage & Usage:


Therapy should be initiated under experienced medical guidance in the treatment of patient with Chronic Myeloid Leukemia (CML).


The prescribed dose should be administered orally, with a meal and a large glass of water. Doses of 400mg under chronic phase & 600mg under accelerated phase should be administered once daily or as prescribed by your doctor.





GEFTINAT 250mg: Each tablet contains Gefitinib 250mg.





Gefitinib inhibits the intracellular phosphorylation of numerous tyrosine kinases associated with transmembrane cell surface receptors, including the tyrosine kinases associated with the epidermal growth factor receptor (EGFR-TK). EGFR is expressed on the cell surface of many normal cells and cancer cells.





Indications:


GEFTINAT (Gefitinib) is indicated as monotherapy for the treatment of patients with locally advanced or metastatic non-small cell lung cancer.





Dosage & Usage:


The recommended daily dose of GEFTINIB in one 250mg tablet with or without food. Higher doses do not give a better response and may cause increased toxicity. It is advisable to consult your doctor to prescribe the dosage that suits your condition.





Sorafenib is a drug approved for the treatment of primary kidney cancer (advanced renal cell carcinoma) and advanced primary liver cancer (hepatocellular carcinoma).





Sorafenib is a small molecular inhibitor of several Tyrosine protein kinases. (Protein kinases are overactive in many of the molecular pathways that cause cells to become cancerous). Sorafenib works along the multiple signaling pathways to block cell proliferation and tumor angiogenesis. It blocks the receptor tyrosine kinases VEGFR (Vascular Endothelial Growth Factor Receptor) and PDGFR (Platelet Derived Growth Factor Receptor) and the RAF serine/threonine kinases along the RAF/MEK/ERK pathway.





Indications :


RCC Locally Advanced / Metastatic clear cell Renal cell carcinoma in patients, who have failed or unsuitable for cytokine therapy.


HCC Unresectable hepatocellular carcinoma.





Dosage & Usage :


400mg twice daily.


High fat meal may decrease oral bioavailability of Sorafenib.


Orally at least 1 hour before or 2 hours after a meal.





AUREL MED SHIELD PVT. LTD. is focussed on increasing the momentum in the Generics Business in its Key Markets. Growth is well spread across geographies with focus on Developed and Emerging Markets.





Our mission is to make the most meaningful difference to healthcare through medicines that bring benefit to patients and add value to the society.


Veenat


Soranib


Geftinat






Report this article Ask About This Article


Loading...
More to Explore